EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 4-Nov-2025 19:11 ET (5-Nov-2025 00:11 GMT/UTC)

1-Jun-2025

Dual-target CAR T cell therapy slows growth of aggressive brain cancer

University of Pennsylvania School of Medicine
Peer-Reviewed Publication

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

Journal: Nature Medicine
Meeting: 2025 ASCO Annual Meeting

31-May-2025

ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according to new research from The University of Texas MD Anderson Cancer Center.

31-May-2025

ADC combination outperforms standard treatment of advanced triple-negative breast cancer

Dana-Farber Cancer Institute
Reports and Proceedings

Dana-Farber Cancer Institute presents potentially practice changing results from the phase 3 ASCENT-04/KEYNOTE-D19 clinical trial at American Society of Clinical Oncology (ASCO) annual meeting

Meeting: 2025 ASCO Annual Meeting

31-May-2025

‘Magnificent 7’ combo treatment for pancreatic cancer presented today at international forum by HonorHealth Research Institute

HonorHealth Research Institute
Reports and Proceedings

A new 7-drug treatment for pancreatic cancer dubbed The Magnificent 7 (MAG 7) will be presented today by HonorHealth Research Institute at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for cancer patients.

Funder: TGen Pancreas National Advisory Council, Purple Pansies Foundation

31-May-2025

Insights from immunotherapy trial inform new approaches to treating advanced skin cancer

University of Pittsburgh
Peer-Reviewed Publication

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma, those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

Journal: Journal of Clinical Oncology
Funder: NIH/National Cancer Institute
Meeting: 2025 ASCO Annual Meeting

31-May-2025

Alliance trial shows dual immunotherapy improves progression-free survival in advanced squamous cell skin cancer

Alliance for Clinical Trials in Oncology
Peer-Reviewed Publication

May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.

Funder: NIH/National Cancer Institute
Meeting: 2025 ASCO Annual Meeting

30-May-2025

ASCO 2025: Pancreatic cancer blood tests, genetic predictors of breast cancer survival and sarcoma treatment response prediction tools among Ohio State findings

Ohio State University Wexner Medical Center
Meeting Announcement

COLUMBUS, Ohio – Pancreatic cancer blood tests, genetic predictors of breast cancer survival and sarcoma treatment response prediction tools are among the research topics being presented by scientists from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 30-June 3 in Chicago.

Meeting: 2025 ASCO Annual Meeting

30-May-2025

UC Davis clinical trial shows biomarkers hold clue in treating aggressive prostate cancer

University of California - Davis Health
Reports and Proceedings

Gene mutations are likely to play a key role in treating aggressive prostate cancer, according to a new UC Davis clinical trial creating hope for men. Findings to be presented at ASCO.

Meeting: 2025 ASCO Annual Meeting

30-May-2025

Mass General Brigham researchers present key findings at ASCO

Mass General Brigham
Meeting Announcement

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30-May-2025

Transforming immunotherapy design

University of Pittsburgh
Grant and Award Announcement

Through

Miskov-Zivanov's novel approach and the development of an automated system that leverages AI and knowledge graphs to design more effective lymphocytes, she hopes to transform the design of life-saving immunotherapies.

Funder: U.S. National Science Foundation